Avectas

About:

Avectas is a cell engineering technology company that enables drug developers to manufacture potent engineered cell therapies.

Website: https://www.avectas.com/

Twitter/X: avectas

Top Investors: EASME - EU Executive Agency for SMEs, Disruptive Technologies Innovation Fund, Seamus Mulligan

Description:

Avectas is a cell engineering technology company, enabling drug developers to manufacture potent engineered cell therapies at therapeutic volumes, with high efficiency and with minimal cell disruption. Avectas technology delivers advanced molecules such as mRNA, proteins and gene editing tools to a range of cell types including T cells for immuno-oncology applications. Unlike the current industry standard of vector-free delivery methods, cells engineered with Avectas technology require no recovery time, leading to a shorter, simpler, more cost effective process.

Total Funding Amount:

$38.9M

Headquarters Location:

Maynooth, Kildare, Ireland

Founded Date:

2010-01-01

Founders:

Michael Maguire, Shirley O'Dea

Number of Employees:

11-50

Last Funding Date:

2021-04-22

IPO Status:

Private

Industries:

© 2025 bioDAO.ai